Acer Therapeutics Obtains Exclusive License to Celiprolol Pivotal Clinical Data from AP-HP | oneedsvoice

welcome to oneEDSvoice

- a positively charged Ehlers Danlos Syndrome community.
  • join today!
view full news & meetings section

Acer Therapeutics Obtains Exclusive License to Celiprolol Pivotal Clinical Data from AP-HP


“We have studied celiprolol for nearly two decades in vEDS patients and this is the only drug ever to demonstrate a clinical benefit in a randomized, controlled clinical study,” said Pierre Boutouyrie M.D., Ph.D., co-director of the clinical pharmacology service at the Georges-Pompidou European Hospital AP-HP and Principal Investigator for the celiprolol study. “Having established celiprolol as a standard of care in France for vEDS patients, we are excited to partner with Acer to help bring celiprolol to members of the U.S. patient community who are suffering from this devastating, life-threatening disease.”

http://mms.businesswire.com/media/20161213005108/en/559489/2/acer-tx-logo.jpg

expertly curated content related to this topic